Cambridge Enterprise, the commercialization office for the University of Cambridge, U.K., has completed the first investment from its Discovery Fund into PneumaCare Limited. The investment will help to develop PneumaScan, a non-invasive lung function measuring and monitoring device. According to Dr. Gareth Roberts, PneumaCare’s CEO, current technology is inadequate for monitoring premature infants, children, and chest injury victims accurately without invasive action, such as tubes. PneumaScan allows fast and non-invasive measurement of lung function using a combination of technologies from the gaming and movie industries, coupled with image processing. “We believe the PneumaScan will make monitoring feasible, effective, and simpler, leading to better patient recovery,” Roberts says. The company was formed from a consortium that includes researchers from Cambridge University’s engineering department, Plextek Limited in Great Chesterford, U.K., and Addenbookes Hospital in Cambridge. The investment by the Discovery Fund, a seed fund that was launched this spring, was made alongside the Cambridge Capital Group, an angel investment network.<\/p>\n